At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 28 enrolled
Drug / intervention
TRV027 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigating the Relationship Between the Renin Angiotensin System and the Coagulopathy Associated With COVID-19
In Brief
A Early Phase 1 clinical trial evaluating TRV027 and sodium chloride 0.9% for COVID. Completed, enrolled 28 participants across 1 site.
Detailed Summary
To determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID
CountriesUnited Kingdom
Collaborators--
Timeline
Early Ph 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartOct 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedJun 5, 2020
Enrollment StartOct 9, 2020
Primary CompletionMay 12, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 6.1 years ago
Interventions
TRV027biological
peptide for infusion
sodium chloride 0.9%other
placebo comparator for infusion